Physician profile
Erick R Singh
NPI 1588862619
$9,281.53
in general payments reported to CMS, 2019-2025
40 companies · $2,117 in 2025
The $2,117 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,326 · 2020: $267 · 2021: $647 · 2022: $1,337 · 2023: $1,236 · 2024: $2,350 · 2025: $2,117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,660 · Education: $43.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,659.62 |
| Education | $43.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,779.65 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,214.84 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $579.48 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $491.42 | 2019-2025 | Entyvio, Eohilia |
| Merck Sharp & Dohme LLC | $415.81 | 2019-2024 | Dificid |
| Janssen Biotech, INC. | $334.54 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Ardelyx, INC. | $321.32 | 2023-2025 | Ibsrela |
| Lilly USA, LLC | $298.53 | 2023-2025 | Omvoh |
| Qol Medical, LLC | $297.60 | 2019-2025 | Sucraid, Sucraid |
| Boston Scientific Corporation | $230.82 | 2019-2024 | Exalt Model D, Resolution 360 Clip |
| Ironwood Pharmaceuticals, INC | $215.36 | 2021-2024 | Linzess |
| Celgene Corporation | $185.55 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $166.95 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $162.12 | 2024-2025 | Zenpep, Vowst |
| Genzyme Corporation | $155.29 | 2023-2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $152.64 | 2021-2023 | |
| Madrigal Pharmaceuticals | $132.93 | 2024-2025 | Rezdiffra, Resmetirom |
| Celltrion USA INC. | $122.31 | 2024-2025 | Vegzelma, Zymfentra |
| Regeneron Healthcare Solutions, INC. | $113.70 | 2025 | Dupixent |
| Gilead Sciences, INC. | $108.62 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $101.70 | 2023-2025 | Voquezna |
| Romark Laboratories, Lc | $100.96 | 2019-2020 | |
| Ethicon US, LLC | $95.39 | 2019 | |
| Daiichi Sankyo INC. | $73.99 | 2023-2024 | Injectafer |
| Ferring Pharmaceuticals INC. | $57.75 | 2021-2023 | Rebyota |
| Ipsen Biopharmaceuticals, INC | $48.17 | 2024-2025 | Iqirvo |
| Fresenius Kabi USA, LLC | $46.54 | 2024 | Idacio |
| Echosens North America, INC. | $38.25 | 2019 | |
| Vivus LLC | $36.94 | 2021 | |
| Ucb, INC. | $27.97 | 2019 | |
| Angiodynamics, INC. | $25.20 | 2022 | |
| Medtronic, INC. | $22.67 | 2024 | Pillcam |
| Amgen INC. | $21.07 | 2023 | Amjevita, Avsola |
| Evoke Pharma, INC. | $19.71 | 2023 | Gimoti |
| Mylan Institutional INC. | $18.79 | 2023 | Hulio |
| Novo Nordisk INC | $16.88 | 2025 | Wegovy |
| Endo Pharmaceuticals INC. | $13.54 | 2019 | |
| Concordia Pharmaceuticals INC. | $13.08 | 2019 | |
| Shionogi INC | $13.06 | 2019 | |
| Intra-Sana Laboratories | $10.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erick Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.